سعر برولوكين محلول تنقيط وريدي 2022

Aldesleukin (recombinant human interleukin-2) for intravenous infusion, listed in Egypt under Novartis; used for metastatic renal cell carcinoma and metastatic melanoma.

• Treatment of adults with metastatic renal cell carcinomaPopulation: AdultsDailyMed (NLM)
• Treatment of adults with metastatic melanomaPopulation: AdultsDailyMed (NLM)

• Severe hypersensitivity to aldesleukin; organ allografts; significant cardiac, pulmonary, renal, hepatic or CNS impairment.International label, equivalent formulation · DailyMed (NLM)

• Boxed warning: capillary leak syndrome (may be fatal), neurologic toxicities (may cause coma) and serious infections; use only in hospital with ICU facilities.International label, equivalent formulation · DailyMed (NLM)
• Renal toxicity, immune-mediated adverse reactions (may exacerbate autoimmune disease), severe hypersensitivity, and embryo-fetal toxicity.International label, equivalent formulation · DailyMed (NLM)

• GlucocorticoidsAvoid concomitant use; may reduce antitumor effectiveness.DailyMed (NLM)
• Iodinated contrast mediaMonitor for delayed adverse reactions after contrast given following aldesleukin.DailyMed (NLM)

• May cause fetal harm or pregnancy loss based on animal data and mechanism; capillary leak syndrome during pregnancy may harm the fetus.International label, equivalent formulation · DailyMed (NLM)
• Advise women not to breastfeed during treatment.International label, equivalent formulation · DailyMed (NLM)